Table 4 Subgroup analysis of association between HBIaC level and MACE.

From: Impact of haemoglobinA1c on platelet reactivity and cardiovascular outcomes in patients undergoing drug-eluting stent implantation

Subgroups

N

HbA1c < 6.5

6.5 ≤ HbA1c ≤ 8.5

HR (95% CIs)

HbA1c > 8.5

HR (95% CIs)

P for interaction

Age (years)

0.356

 < 61

794

Reference

1.87 (0.89, 3.72)

3.12 (1.93, 5.69)

 

 ≥ 61

827

Reference

1.63 (0.82, 2.96)

3.00 (1.79, 4.67)

 

Gender

0.576

 Male

425

Reference

1.68 (1.05, 2.70)

2.64 (1.37, 5.07)

 

 Female

1196

Reference

1.57 (0.78, 3.19)

4.18 (1.91, 9.14)

 

Diabetic status

0.571

 Diabetics

481

Reference

2.78 (1.36, 5.12)

5.08 (2.67, 9.98)

 

 Non-diabetics

1140

Reference

1.63 (0.96, 2.79)

4.70 (2.41, 8.87)

 

Obesity status

0.756

 BMI < 30 kg/m2

1358

Reference

1.72 (1.21, 2.76)

3.15 (1.71, 5.75)

 

 BMI ≥ 30 kg/m2

263

Reference

1.64 (0.79, 3.56)

2.88 (1.21, 6.09)

 

Hypertension status

0.932

 Hypertension

1113

Reference

1.59 (1.02, 2.50)

3.29 (1.89, 5.81)

 

 Non-hypertension

508

Reference

1.78 (0.91, 3.91)

2.94 (1.35, 7.84)